Maxigesic mainlined into US hospitals as AFT Pharma signs US$19m IV deal
Delays making deal affected guidance at last results briefing.
Dita De Boni
Wed, 28 Apr 2021
An increasing awareness of the dangers of opioid pain relief in the US healthcare system has provided an opening for NZX-listed drug maker AFT Pharmaceuticals, which today announced it has signed an almost US$19 million deal to supply its main product Maxigesic for use in hospital IV systems in the
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
NZ Aviation News
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Aviation News - Monthly
NZ$14.95 / monthly
Already have an account? Login
Dita De Boni
Wed, 28 Apr 2021
Contact the Writer: dita@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Maxigesic mainlined into US hospitals as AFT Pharma signs US$19m IV deal
Business,
87166